Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Alice Schwartz

David Schwartz

Bio-Rad Laboratories, Inc.

Bio-Rad Antibodies

Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together.

#Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics

Bio-Rad Laboratories

Bio-Rad's Global Supply Chain is a diverse, multidisciplinary team responsible for getting Bio-Rad products into the hands of our customers. We're #hiring. Check out our open warehouse, production and manufacturing roles: https://ow.ly/BVBv50PNxNI

#EmpoweredByPurpose #LifeAtBioRad

Do you want to learn more about #LifeAtBioRad? Check out our blog for employee profiles, job search tips, community involvement, and more: https://ow.ly/hGwK50QCpCG

#EmpoweredByPurpose #Hiring

Have you experienced an unacceptable #QC result in your lab? Troubleshooting an out-of-control event in a clinical laboratory requires a systematic approach to recover from the event and prevent its recurrence. Learn more about how to recover from an out-of-control QC event in your lab: https://bit.ly/4bIUhb8

#labquality #qualitycontrol #labmanagement #ClinicalLabTesting #QualityControl #ReliableResults #ContinuousLearning

Applications for our 2024 scholarships are now open in the U.S.! Apply by April 1. 

Since 2003, Bio-Rad has proudly awarded more than 250 college scholarships to graduating high school students interested in pursuing careers in science and engineering. Learn more about our scholarship program on the #LifeAtBioRad blog: https://ow.ly/RKWz50QBl8p

#EmpoweredByPurpose #Hiring

Precise and reliable detection of minimal residual disease (MRD) is essential for assessing disease status in hematological malignancies. Droplet Digital PCR technology has demonstrated high utility for sensitive molecular MRD analysis in oncology research. In this study, researchers compared qPCR to ddPCR technology for MRD detection at multiple time points in acute lymphoblastic leukemia samples. Though the two methods showed high concordance, ddPCR demonstrated better sensitivity by detecting MRD in certain samples missed by qPCR.  

Read the article here: https://ow.ly/cO1950QAiS0

#MolecularResidualDisease #Hematology #ddPCR

Bio-Rad engineers work cross-functionally with scientists and other product experts to deliver innovative solutions that improve healthcare outcomes for people around the world. To see our #engineering jobs and other open roles, visit: https://ow.ly/FBVv50Qrwwm. Apply today!

#EmpoweredByPurpose #Hiring #LifeAtBioRad

📚 Dive into the Latest Edition of Bio-Rad Reads: Vericheck ddPCR Contaminant Testing Solutions Edition! This month, we're spotlighting Bio-Rad's Vericheck product portfolio and its pivotal role in the biopharma workflow. 

In this edition, explore:
-In-process testing of cell lines for biotherapeutic production
-QA/QC testing to assess therapeutic product safety and purity
-Bio-Rad’s comprehensive Vericheck ddPCR Contaminant testing solutions portfolio

#biorad  #biopharma #ddPCR #ContaminantTesting #Vericheck

How can you ensure the reliability of QC results every day when the average proficiency program only tests samples monthly or bi-weekly? Increase reliability of QC performance between these testing windows with a peer comparison tool like Unity Next Peer QC.

Labs can see shifts and trends in QC performance before they impact patient test results. Learn more about increasing reliability of QC test results everyday with Unity Next Peer QC: https://bit.ly/495088P

#qualitycontrol #datamanagement #clinicaldiagnostics #QCdata #clinicaloperations #clinicallaboratory #labautomation #QC

It's been raining here at Bio-Rad in Hercules, CA but our HR colleagues always manage to find the silver lining. 🌧🌈. Here's two recent shots, plus a few favorites from last winter.
Ready to help us find the pot of gold? We're #Hiring: https://ow.ly/ubx750QC7VW

#LifeAtBioRad #EmpoweredByPurpose

Mycoplasma contamination in cell culture can derail a successful biopharma project, but choosing an approach for mycoplasma detection can be a challenge. Bio-Rad is here to help! Check out this video for some key considerations in choosing a mycoplasma detection strategy that fits your needs: https://ow.ly/wQjE50QAirl

#Biopharma #ddPCR #Mycoplasma

Metric
Company Name	Bio-Rad Laboratories, Inc.
Symbol	BIO
MSH ID	COM:BIO-RAD
Market	STOCKS
Sector	Healthcare
Industry	Medical - Devices
Country	US
Stage
Employee Count	8K
Website	bio-rad.com
LinkedIn	bio-rad
Founders

Metric
Market Cap	8.01B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	2.67B
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.43B
EBITDA	576.20M
Operating Income	383.80M
Net Income	-637.32M
EPS	-21.82
Diluted EPS	-21.82
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.54
Operating Profit Margin	0.15
EBITDA Margin	0.22
Net Profit Margin	-0.12
Return on Equity	-0.04
Return on Assets	-0.03
Return on Capital Employed	0.04

NYSE:BIO.B

Bio-Rad Laboratories, Inc.

Last Close

325.58

22/11 21:00

Market Cap

8.01B

Beta: -

Volume Today

184.50K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-58.35
P/B Ratio	1.10
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.81
EV Multiple	16.32

Metric
Days Sales Outstanding	61.37
Days Payables Outstanding	77.12
Days Inventory Outstanding	248.85
Operating Cycle	313.70
Cash Conversion Cycle	274.47
Asset Turnover	0.26

Metric
Operating Cash Flow	374.94M
Free Cash Flow	218.26M
Cash Flow to Debt	0.30
Operating Cash Flow/Sales	0.14
Free Cash Flow Yield	0.02

Metric
Cash & Equivalents	403.97M
Accounts Receivable	11.40M
Inventory	780.52M
Goodwill	413.60M
Debt to Capitalization	0.15
Debt to Assets	0.10
Current Ratio	5.64
Quick Ratio	4.89

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02
R&D to Revenue	0.09
SG&A to Revenue